Altria Launches on! PLUS, Files FDA for Heated Tobacco

Altria’s on! PLUS launch signals continued emphasis on growth in modern oral nicotine products as the company pivots from combustible cigarettes. The company markets on! as part of its oral nicotine pouch portfolio alongside existing brands. For investors, the headline actions are product-line expansion (on! PLUS) and parallel regulatory steps (FDA filings for heated tobacco). These moves reflect management’s stated strategic priority to shift away from declining combustible volumes — cigarette shipments declined to 68.6 billion units in 2024, down 10.2% year-over-year — toward smoke-free alternatives (on!, NJOY e-vapor, and Horizon heated tobacco sticks).

Altria’s submission of premarket applications to FDA for heated tobacco is a necessary regulatory step; filings do not imply authorization or immediate commercialization. As disclosed in prior filings, Horizon had no FDA-authorized heated tobacco products as of February 2025. Commercial rollout of heated tobacco consumables by PM USA would be contingent on FDA review and clearance. The Horizon joint venture structure (Altria holding a 75% economic interest) means regulatory outcomes will materially affect timing and value capture for Altria’s smoked-to-smoke-free transition. Investors should expect regulatory timelines and potential requests for additional data to influence when any consumer-facing commercialization could begin.

Altria has been redeploying capital as it reshapes the portfolio. The company used proceeds from a partial sale of its AB InBev stake in March 2024 to fund $2,410 million in share repurchases (54.1 million shares) and continued repurchases of $600 million (approximately 10.4 million shares) in H1 2025, per filings. Dividends and distributions from subsidiaries remain a stated priority, and there were no contractual limits on such distributions as of June 30, 2025. Strategically, the combination of on! product expansion, NJOY e-vapor ownership, and the Horizon heated tobacco program positions Altria to offer a range of reduced-combustion alternatives. However, near-term revenue impact depends on FDA outcomes and the pace of consumer adoption against a backdrop of secular cigarette volume declines.

Regulatory risk: Heated tobacco commercialization hinges on FDA authorization; absence of authorization as of Feb 2025 remains a gating factor. Legal and environmental risk: Filings continue to disclose legal contingencies, including appeal bonds collateralized by restricted cash (e.g., $9 million in other current assets and $15–23 million in other assets as of June 30, 2025) and potential Superfund and natural resource remediation obligations. Operational risk: Cigarette volumes are falling (2024 shipments down 10.2%), a rising workplace injury rate (1.8% in 2024 vs. 1.2% in 2023), and a meaningful unionized manufacturing workforce (about 26% of ~6,200 employees) are operational factors to monitor. Investment risk: Equity investments (ABI stake, partially sold in 2024, and Cronos Group) and prior strategic moves such as the NJOY-related cash outflow referenced in filings (historical net cash outflow noted) expose Altria to market and integration risks.